C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci177429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Cheng Tang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathobiology, College of Dentistry, and. Hauptthemen laut MEDLINE: Calcium Channels, N-Type, Calcium Channel Blockers, Pain, Analgesics. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIDCR NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
Antagonists — such as Ziconotide and Gabapentin — of the Ca V 2.2 (N-type) calcium channels are used clinically as analgesics for chronic pain. However, their use is limited by narrow therapeutic windows, difficult dosing routes (Ziconotide), misuse, and overdoses (Gabapentin), as well as a litany of adverse effects. Expansion of novel pain therapeutics may emerge from mechanism-based interrogation of Ca V 2.2. Here, we report the identification of C2230, an aryloxy-hydroxypropylamine, as a Ca V 2.2 blocker. C2230 trapped and stabilized inactivated Ca V 2.2 in a slow-recovering state and accelerated the open-state inactivation of the channel, conferring an advantageous use-dependent inhibition profile. C2230 inhibited Ca V 2.2 during high-frequency stimulation, while sparing other voltage-gated ion channels. C2230 inhibited Ca V 2.2 in dorsal root and trigeminal ganglia neurons from rats, marmosets, and humans in a G-protein-coupled-receptor–independent manner. Further, C2230 reduced evoked excitatory postsynaptic currents and excitatory neurotransmitter release in the spinal cord, leading to relief of neuropathic, orofacial, and osteoarthritic pain-like behaviors via 3 different routes of administration. C2230 also decreased fiber photometry-based calcium responses in the parabrachial nucleus, mitigated aversive behavioral responses to mechanical stimuli after neuropathic injury, and preserved protective pain responses, all without affecting motor or cardiovascular function. Finally, site-directed mutation analysis demonstrated that C2230 binds differently than other known Ca V 2.2 blockers, making it a promising lead compound for analgesic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pathobiology, College of Dentistry, and.
- Pain Research Center, New York University, New York, New York, USA.
- The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China.
- Department of Pharmacology and Therapeutics, College of Medicine and.
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Center for Orofacial Pain and Temporomandibular Disorders, Department of Diagnostic Sciences, Rutgers School of Dental Medicine, Newark, New Jersey, USA.
Förderung
- NINDS NIH HHS
- NIDCR NIH HHS
- NIDA NIH HHS
- NINDS
- NIDA
Zitieren
APA
Tang, C., Gomez, K., Chen, Y., Allen, H. N., Hestehave, S., Rodríguez-Palma, E. J., Loya-Lopez, S., Calderon-Rivera, A., Duran, P., Nelson, T. S., Kanumuri, S. R. R., Shah, B., Panigrahi, N. R., Perez-Miller, S., Schackmuth, M. K., Ruparel, S., Patwardhan, A., Price, T. J., Arora, P. S., …, & Khanna, R. (2025). C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models. Journal of Clinical Investigation. https://doi.org/10.1172/jci177429
Vancouver
Tang C, Gomez K, Chen Y, Allen HN, Hestehave S, Rodríguez-Palma EJ, et al. C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models. Journal of Clinical Investigation. 2025. doi:10.1172/jci177429
BibTeX
@article{Tang2025,
author = {Tang, Cheng and Gomez, Kimberly and Chen, Yan and Allen, Heather N and Hestehave, Sara and Rodríguez-Palma, Erick J and Loya-Lopez, Santiago and Calderon-Rivera, Aida and Duran, Paz and Nelson, Tyler S and Kanumuri, Siva Rama Raju and Shah, Bijal and Panigrahi, Nihar R and Perez-Miller, Samantha and Schackmuth, Morgan K and Ruparel, Shivani and Patwardhan, Amol and Price, Theodore J and Arora, Paramjit S and Sharma, Ravindra K and Sharma, Abhisheak and Yu, Jie and Korczeniewska, Olga A and Khanna, Rajesh},
title = {C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci177429}
}
EUVIMED